Headquartered in Neuhofstrasse 21, Baar Fiscal year ends December NASDAQ: NVCR novocure.com
Novocure is a global oncology company focused on extending survival in aggressive forms of cancer through the development and commercialization of Tumor Treating Fields (TTFields), a non-invasive, antimitotic therapy that uses electric fields to disrupt cancer cell division. The company's commercialized product portfolio includes Optune Gio for glioblastoma, Optune Lua for metastatic non-small cell lung cancer, and Optune Pax for locally advanced pancreatic cancer. These wearable, portable devices are approved in multiple countries and are used in combination with standard-of-care chemotherapy and immunotherapy regimens. Novocure generates revenue through direct commercialization in markets including the United States, Germany, France, and Japan, and through a partnership with Zai Lab in Greater China. The company has an active clinical pipeline exploring TTFields in additional indications including brain metastases from NSCLC, with an FDA decision anticipated in late 2026. Updated
Tuesday's top analyst upgrades and downgrades included Academy Sports and Outdoors, Boston Scientific, Ciena, CrowdStrike, Emerson Electric, Kimco Realty, Nike, NovoCure and Zimmer Biomet.
Wednesday's top analyst upgrades and downgrades included Amazon.com, Beyond Meat, Compass, DraftKings, Genius Sports, Home Depot, International Flavors & Fragrances, Lowe's, Palantir Technologies, Telephone and Data Systems and Walmart.
Monday's top analyst upgrades and downgrades included Amazon.com, Amgen, Apple, BioCryst Pharmaceuticals, Block, Coinbase Global, Datadog, Fortinet, Gilead Sciences, Intercontinental Exchange, Moderna, Monster Beverage, Nvidia, PayPal and Petrobras.
Tuesday's top analyst upgrades and downgrades included Adobe, Airbnb, Apple, Capri, Carvana, Chevron, Expedia, GE Healthcare Technologies, Hasbro, Monster Beverage, Nutrien, Salesforce, Tencent Music Entertainment, Valero Energy and Wayfair.
Wednesday's top analyst upgrades and downgrades included Amgen, Canadian Pacific Kansas City, Carvana, Coinbase Global, Etsy, First Horizon, GE Healthcare Technologies, Gilead Sciences, Home Depot, Mosaic, Royal Caribbean Cruises, Vornado Realty Trust,…
Monday's top analyst upgrades and downgrades included Alphabet, Bill, Bumble, Dollar General, FedEx, FMC, Jabil Circuit, Microsoft, Nike, Nvidia, Sarepta Therapeutics, Shopify, Synchrony Financial, Warner Bros. Discovery and Zscaler.
Friday's top analyst upgrades and downgrades included Ally Financial, American Express, AppLovin, AstraZeneca, Coinbase Global, Cognizant Technology Solutions, Comcast, CME, CrowdStrike, Delta Air Lines, Danaher, Dropbox, Marathon Oil, Microsoft and Target.
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, Analog Devices, Analog Devices, Chevron, Danaher, FedEx, Intel, Meta Platforms, NXP Semiconductors, Qualcomm, Southern, Texas Instruments, WeWork, Wolfspeed, Zscaler.
Monday's top analyst upgrades and downgrades included AT&T, ADM, Chevron, FedEx, Intel, Meta, Qualcomm and more.
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, Block, Bumble, DigitalOcean, Duke Realty, FirstEnergy, HF Sinclair, Nio, Petco Health and Wellness, Roblox, Rocket Companies, SoFi Technologies and Walt Disney.
Thursday's top analyst upgrades and downgrades included Advanced Micro Devices, Beyond Meat, Colgate-Palmolive, Edwards Lifesciences, Electronic Arts, Exxon Mobil, Meta Platforms, PayPal and Starbucks.
Tuesday's top analyst upgrades and downgrades included Broadcom, Carrier Global, Canadian Pacific Railway, Coca-Cola, Eli Lilly, Marvell Technology, Pfizer, Regions Financial, Stryker, Synchrony Financial, Tesla and Zillow.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including NovoCure, Synchrony, Twitter and Yum! Brands.
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, Alexion Pharmaceuticals, Avis Budget, DexCom, Johnson & Johnson, Marvell Technology, Moderna, Snap, Splunk and Zoom Video Communications.
Novocure is a global oncology company focused on extending survival in aggressive forms of cancer through the development and commercialization of Tumor Treating Fields (TTFields), a non-invasive, antimitotic therapy that uses electric fields to disrupt cancer cell division.
The Wall Street consensus 12-month price target for NVCR is $26.86.
